Anneke van der Walt

Summary

Affiliation: Royal Melbourne Hospital
Country: Australia

Publications

  1. doi request reprint A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor
    Anneke van der Walt
    Royal Melbourne Hospital, Melbourne, Australia
    Neurology 79:92-9. 2012
  2. doi request reprint Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy
    A van der Walt
    Royal Melbourne Hospital, Department of Neurology, Parkville, Vic, Australia
    Neurology 73:1018-25. 2009
  3. doi request reprint Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade
    Anneke van der Walt
    The Royal Melbourne Hospital, Grattan St Parkville, Melbourne, Australia Centre for Neuroscience, University of Melbourne, Australia
    Pharmacol Ther 126:82-93. 2010
  4. doi request reprint Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition
    Anneke van der Walt
    Department of Neurology, The Royal Melbourne Hospital, Melbourne, Australia
    Mult Scler 17:344-52. 2011
  5. pmc Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomes
    Anneke van der Walt
    Department of Anatomy and Neuroscience, University of Melbourne, Melbourne, Victoria, Australia Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia Department of Neuro ophthalmology, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia Melbourne Brain Centre at Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia
    PLoS ONE 8:e83825. 2013
  6. pmc Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients
    Cathy J Jensen
    Howard Florey Institute, Melbourne, Australia
    PLoS ONE 5:e10003. 2010
  7. pmc Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes
    Yejun Wang
    The Centre for Neuroscience Research, University of Melbourne, Parkville, Victoria, Australia
    PLoS ONE 7:e52291. 2012
  8. pmc Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis
    Tomas Kalincik
    Departments of Medicine and Neurology, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia
    PLoS ONE 8:e63480. 2013

Collaborators

  • Scott Kolbe
  • J P Rubio
  • Alessandra Lugaresi
  • Steve Vucic
  • Cavit Boz
  • Gerardo Iuliano
  • Liliana Patrucco
  • Merrilee Needham
  • David Williams
  • Lyn R Griffiths
  • Sharon R Browning
  • Simon J Foote
  • Jim Stankovich
  • Melanie Bahlo
  • Matthew A Brown
  • Helmut Butzkueven
  • Tomas Kalincik
  • Mark Paine
  • Yejun Wang
  • Mark Slee
  • Trevor J Kilpatrick
  • Cathy J Jensen
  • Erik van Munster
  • Pierre Duquette
  • Freek Verheul
  • Jeannette Lechner-Scott
  • Fraser Moore
  • Katherine Buzzard
  • Erika Pietrolongo
  • Walter Oleschko Arruda
  • Bhim Singhal
  • Jose Antonio Cabrera-Gomez
  • Damiano Paolicelli
  • Daniela Travaglini
  • Etienne Roullet
  • Joab Chapman
  • Orla Gray
  • Sholmo Flechter
  • Joseph Herbert
  • Olga Skibina
  • Timothy Spelman
  • Lisa Morgan
  • Pietro Iaffaldano
  • François Grand'maison
  • Juan Ignacio Rojas
  • Marcela Fiol
  • Norbert Vella
  • Carmen Adella Sîrbu
  • Elizabeth Alejandra Bacile Bacile
  • Elaine Roger
  • Thor Petersen
  • Lisa Dark
  • Maria Trojano
  • Pierre Grammond
  • Raed Alroughani
  • Celia Oreja-Guevara
  • Maria Edite Rio
  • Dieter Poehlau
  • Eugenio Pucci
  • Jill Byron
  • Maria Di Ioia
  • Pierre Despault
  • Vilija Jokubaitis
  • Valeria Di Tommaso
  • Guillermo Izquierdo
  • Daniele La Spitaleri
  • Eli Skromne
  • Maria Laura Saladino
  • Jorge Correale
  • John King
  • Edgardo Cristiano
  • Krisztian Kasa
  • Mark Marriott
  • Cartechini Elisabetta
  • Maria Pia Amato
  • Luca Mancinelli
  • Trevor Kilpatrick
  • Leontien den Braber-Moerland
  • Tatjana Petkovska-Boskova
  • Raymond Hupperts
  • Célica Ysrraelit
  • Jodi Haartsen
  • Vetere Santiago
  • Vahid Shaygannejad
  • Aldo Savino
  • Vincent van Pesch
  • Cameron Shaw
  • Giovanna De Luca
  • Norma Deri
  • Ricardo Fernández-Bolaños

Detail Information

Publications8

  1. doi request reprint A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor
    Anneke van der Walt
    Royal Melbourne Hospital, Melbourne, Australia
    Neurology 79:92-9. 2012
    ..To evaluate the safety and efficacy of botulinum toxin type A in disabling multiple sclerosis (MS)-related upper limb tremor...
  2. doi request reprint Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy
    A van der Walt
    Royal Melbourne Hospital, Department of Neurology, Parkville, Vic, Australia
    Neurology 73:1018-25. 2009
    ..In this study, we examine the influence of heterogeneity of the APOE gene on disease severity in a large, Australian, population-based MS cohort...
  3. doi request reprint Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade
    Anneke van der Walt
    The Royal Melbourne Hospital, Grattan St Parkville, Melbourne, Australia Centre for Neuroscience, University of Melbourne, Australia
    Pharmacol Ther 126:82-93. 2010
    ..In this article, we will discuss some of the principal therapeutic candidates that could provide neuroprotection in MS and emerging methodologies by which to test them...
  4. doi request reprint Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition
    Anneke van der Walt
    Department of Neurology, The Royal Melbourne Hospital, Melbourne, Australia
    Mult Scler 17:344-52. 2011
    ..We examined the influence of DR15 and other common DRB1 alleles (DRB1*01 (DR1), DRB1*03 (DR3) and DRB1*04 (DR4) on MS severity in a large, Australian, population-based cohort...
  5. pmc Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomes
    Anneke van der Walt
    Department of Anatomy and Neuroscience, University of Melbourne, Melbourne, Victoria, Australia Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia Department of Neuro ophthalmology, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia Melbourne Brain Centre at Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia
    PLoS ONE 8:e83825. 2013
    ..Early markers of axonal and clinical outcomes are required for early phase testing of putative neuroprotective therapies for multiple sclerosis (MS)...
  6. pmc Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients
    Cathy J Jensen
    Howard Florey Institute, Melbourne, Australia
    PLoS ONE 5:e10003. 2010
    ..No associations were significant after correction for multiple testing. We found no evidence for the hypothesis that these new MS disease risk-associated SNPs influence disease severity...
  7. pmc Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes
    Yejun Wang
    The Centre for Neuroscience Research, University of Melbourne, Parkville, Victoria, Australia
    PLoS ONE 7:e52291. 2012
    ..59, p = 0.02). In conclusion, these findings indicate that MTR flux after acute ON is predictive of axonal degeneration and visual disability outcomes...
  8. pmc Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis
    Tomas Kalincik
    Departments of Medicine and Neurology, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia
    PLoS ONE 8:e63480. 2013
    ....